Clinical study of cyclosporine A in treating myelodysplastic syndrome

Objective To study the efficacy of cyclosporine A for treating myelodysplastic syndrome.Methods Eleven patients with myelodysplastic syndrome(RA,RARS,n=9,and RAEB,n=2) were treated with cyclosporine A [3-5 mg/(kg·d)]with stanozolol or prednison for 5-12 months and the blood concentration of cyclosporine A was kept between 150 ng/ml and 300 ng/ml.Results The short-term response was obtained at 1-5 months.In the patients with low-risk refractory anemia,hematological improvement was achieved in 5 out of 8 patients and partial remission 3 out of 8 patients,which was independent of blood transfusion;whereas in the high-risk patients no remission was observed.Conclusion The cyclosporine A regimen is effective in treating the patients with low-risk myelodysplastic syndrome and improves the clinical outcome.